Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.
Ramirez-Valdez RA, Baharom F, Khalilnezhad A, Fussell SC, Hermans DJ, Schrager AM, Tobin KKS, Lynn GM, Khalilnezhad S, Ginhoux F, Van den Eynde BJ, Leung CSK, Ishizuka AS, Seder RA. Ramirez-Valdez RA, et al. Among authors: ishizuka as. Cell Rep. 2023 Jun 27;42(6):112599. doi: 10.1016/j.celrep.2023.112599. Epub 2023 Jun 7. Cell Rep. 2023. PMID: 37279110 Free PMC article.
Correction: Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.
Speake C, Pichugin A, Sahu T, Malkov V, Morrison R, Pei Y, Juompan L, Milman N, Zarling S, Anderson C, MacDonald NJ, Wong-Madden S, Wendler J, Ishizuka A, MacMillen ZW, Garcia V, Kappe SH, Krzych U, Duffy PE. Speake C, et al. PLoS One. 2016 Oct 20;11(10):e0165489. doi: 10.1371/journal.pone.0165489. eCollection 2016. PLoS One. 2016. PMID: 27764243 Free PMC article.
In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity.
Lynn GM, Laga R, Darrah PA, Ishizuka AS, Balaci AJ, Dulcey AE, Pechar M, Pola R, Gerner MY, Yamamoto A, Buechler CR, Quinn KM, Smelkinson MG, Vanek O, Cawood R, Hills T, Vasalatiy O, Kastenmüller K, Francica JR, Stutts L, Tom JK, Ryu KA, Esser-Kahn AP, Etrych T, Fisher KD, Seymour LW, Seder RA. Lynn GM, et al. Among authors: ishizuka as. Nat Biotechnol. 2015 Nov;33(11):1201-10. doi: 10.1038/nbt.3371. Epub 2015 Oct 26. Nat Biotechnol. 2015. PMID: 26501954 Free PMC article.
Protection against malaria at 1 year and immune correlates following PfSPZ vaccination.
Ishizuka AS, Lyke KE, DeZure A, Berry AA, Richie TL, Mendoza FH, Enama ME, Gordon IJ, Chang LJ, Sarwar UN, Zephir KL, Holman LA, James ER, Billingsley PF, Gunasekera A, Chakravarty S, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, K C N, Murshedkar T, DeCederfelt H, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Laurens MB, Plowe CV, Flynn B, Whalen WR, Todd JP, Noor J, Rao S, Sierra-Davidson K, Lynn GM, Epstein JE, Kemp MA, Fahle GA, Mikolajczak SA, Fishbaugher M, Sack BK, Kappe SH, Davidson SA, Garver LS, Björkström NK, Nason MC, Graham BS, Roederer M, Sim BK, Hoffman SL, Ledgerwood JE, Seder RA. Ishizuka AS, et al. Nat Med. 2016 Jun;22(6):614-23. doi: 10.1038/nm.4110. Epub 2016 May 9. Nat Med. 2016. PMID: 27158907 Free PMC article. Clinical Trial.
Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection.
Lyke KE, Ishizuka AS, Berry AA, Chakravarty S, DeZure A, Enama ME, James ER, Billingsley PF, Gunasekera A, Manoj A, Li M, Ruben AJ, Li T, Eappen AG, Stafford RE, Kc N, Murshedkar T, Mendoza FH, Gordon IJ, Zephir KL, Holman LA, Plummer SH, Hendel CS, Novik L, Costner PJ, Saunders JG, Berkowitz NM, Flynn BJ, Nason MC, Garver LS, Laurens MB, Plowe CV, Richie TL, Graham BS, Roederer M, Sim BK, Ledgerwood JE, Hoffman SL, Seder RA. Lyke KE, et al. Among authors: ishizuka as. Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2711-2716. doi: 10.1073/pnas.1615324114. Epub 2017 Feb 21. Proc Natl Acad Sci U S A. 2017. PMID: 28223498 Free PMC article. Clinical Trial.
Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction.
Lynn GM, Chytil P, Francica JR, Lagová A, Kueberuwa G, Ishizuka AS, Zaidi N, Ramirez-Valdez RA, Blobel NJ, Baharom F, Leal J, Wang AQ, Gerner MY, Etrych T, Ulbrich K, Seymour LW, Seder RA, Laga R. Lynn GM, et al. Among authors: ishizuka as. Biomacromolecules. 2019 Feb 11;20(2):854-870. doi: 10.1021/acs.biomac.8b01473. Epub 2019 Jan 22. Biomacromolecules. 2019. PMID: 30608149
Peptide-TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens.
Lynn GM, Sedlik C, Baharom F, Zhu Y, Ramirez-Valdez RA, Coble VL, Tobin K, Nichols SR, Itzkowitz Y, Zaidi N, Gammon JM, Blobel NJ, Denizeau J, de la Rochere P, Francica BJ, Decker B, Maciejewski M, Cheung J, Yamane H, Smelkinson MG, Francica JR, Laga R, Bernstock JD, Seymour LW, Drake CG, Jewell CM, Lantz O, Piaggio E, Ishizuka AS, Seder RA. Lynn GM, et al. Among authors: ishizuka as. Nat Biotechnol. 2020 Mar;38(3):320-332. doi: 10.1038/s41587-019-0390-x. Epub 2020 Jan 13. Nat Biotechnol. 2020. PMID: 31932728 Free PMC article.
Intravenous nanoparticle vaccination generates stem-like TCF1+ neoantigen-specific CD8+ T cells.
Baharom F, Ramirez-Valdez RA, Tobin KKS, Yamane H, Dutertre CA, Khalilnezhad A, Reynoso GV, Coble VL, Lynn GM, Mulè MP, Martins AJ, Finnigan JP, Zhang XM, Hamerman JA, Bhardwaj N, Tsang JS, Hickman HD, Ginhoux F, Ishizuka AS, Seder RA. Baharom F, et al. Among authors: ishizuka as. Nat Immunol. 2021 Jan;22(1):41-52. doi: 10.1038/s41590-020-00810-3. Epub 2020 Nov 2. Nat Immunol. 2021. PMID: 33139915 Free PMC article.
24 results